A. Ardizzoni Et Al. , "Interim safety results from TRUST, a global open-label study of erlotinib in patients with advanced non-small-cell lung cancer (NSCLC)," JOURNAL OF THORACIC ONCOLOGY , vol.2, no.8, 2007
Ardizzoni, A. Et Al. 2007. Interim safety results from TRUST, a global open-label study of erlotinib in patients with advanced non-small-cell lung cancer (NSCLC). JOURNAL OF THORACIC ONCOLOGY , vol.2, no.8 .
Ardizzoni, A., Razis, E., Lichinitser, M., Yilmaz, U., Grigorescu, A. C., Morero, J. L., ... Skrickova, J.(2007). Interim safety results from TRUST, a global open-label study of erlotinib in patients with advanced non-small-cell lung cancer (NSCLC). JOURNAL OF THORACIC ONCOLOGY , vol.2, no.8.
Ardizzoni, Andrea Et Al. "Interim safety results from TRUST, a global open-label study of erlotinib in patients with advanced non-small-cell lung cancer (NSCLC)," JOURNAL OF THORACIC ONCOLOGY , vol.2, no.8, 2007
Ardizzoni, Andrea Et Al. "Interim safety results from TRUST, a global open-label study of erlotinib in patients with advanced non-small-cell lung cancer (NSCLC)." JOURNAL OF THORACIC ONCOLOGY , vol.2, no.8, 2007
Ardizzoni, A. Et Al. (2007) . "Interim safety results from TRUST, a global open-label study of erlotinib in patients with advanced non-small-cell lung cancer (NSCLC)." JOURNAL OF THORACIC ONCOLOGY , vol.2, no.8.
@article{article, author={Andrea Ardizzoni Et Al. }, title={Interim safety results from TRUST, a global open-label study of erlotinib in patients with advanced non-small-cell lung cancer (NSCLC)}, journal={JOURNAL OF THORACIC ONCOLOGY}, year=2007}